Loading...
XHKG1011
Market cap9mUSD
Dec 23, Last price  
0.29HKD
1D
9.43%
1Q
26.09%
Jan 2017
-98.04%
IPO
-99.24%
Name

China NT Pharma Group Company Ltd

Chart & Performance

D1W1MN
XHKG:1011 chart
P/E
—
P/S
9.76
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-33.88%
Rev. gr., 5y
-58.12%
Revenues
7m
-96.44%
2,667,978,0002,758,142,000739,132,000754,115,000864,621,000847,726,000915,119,000604,846,000571,521,000365,969,000221,731,000226,699,000207,092,0007,366,000
Net income
-144m
L+116.23%
128,610,000234,377,000-1,109,316,000-673,458,0002,087,00087,694,000116,181,000165,195,000-957,666,000-593,202,000-191,269,000-151,334,000-66,405,000-143,590,000
CFO
50m
+39.40%
-383,235,000-206,326,000-6,842,000-38,480,00072,723,000-97,398,00020,693,000147,561,000-124,203,00047,765,00026,204,000-134,775,00036,210,00050,476,000
Dividend
Jul 10, 20180.035 HKD/sh

Profile

China NT Pharma Group Company Limited, together with its subsidiaries, engages in the research and development, manufacturing, sales, and distribution of pharmaceutical products in the People's Republic of China and internationally. It manufactures, sells, and trades in prescription medicines for the tumor and blood system diseases, digestive system diseases, central nervous system diseases, diseases of respiratory system, and other therapeutic fields; and produces and sells NT branded products and generic drugs. The company also provides marketing and promotion services to suppliers, and logistics and consulting services. China NT Pharma Group Company Limited was founded in 1995 and is headquartered in Suzhou, the People's Republic of China.
URL
http://www.ntpharma.com/
IPO date
Apr 20, 2011
Employees
124
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
7,366
-96.44%
207,092
-8.65%
226,699
2.24%
Cost of revenue
63,574
191,685
317,721
Unusual Expense (Income)
NOPBT
(56,208)
15,407
(91,022)
NOPBT Margin
7.44%
Operating Taxes
122
12,109
2,582
Tax Rate
78.59%
NOPAT
(56,330)
3,298
(93,604)
Net income
(143,590)
116.23%
(66,405)
-56.12%
(151,334)
-20.88%
Dividends
Dividend yield
Proceeds from repurchase of equity
9,393
2,021
BB yield
-8.63%
-0.12%
Debt
Debt current
341,342
825,991
618,430
Long-term debt
4,616
1,872
215,675
Deferred revenue
(77,220)
213,290
Other long-term liabilities
77,220
(213,290)
Net debt
30,892
544,350
546,205
Cash flow
Cash from operating activities
50,476
36,210
(134,775)
CAPEX
(10,733)
(4,494)
(646)
Cash from investing activities
(22,140)
4,530
257,814
Cash from financing activities
(28,972)
(46,676)
(124,798)
FCF
479,521
16,374
417,932
Balance
Cash
1,520
5,931
9,443
Long term investments
313,546
277,582
278,457
Excess cash
314,698
273,158
276,565
Stockholders' equity
(2,505,604)
(2,093,856)
(2,058,684)
Invested Capital
2,510,981
2,646,406
2,658,653
ROIC
0.12%
ROCE
2.45%
EV
Common stock shares outstanding
197,815
1,899,150
1,889,613
Price
0.55
-38.89%
0.90
26.76%
0.71
-40.83%
Market cap
108,798
-93.63%
1,709,235
27.40%
1,341,625
-40.75%
EV
139,690
2,253,585
1,887,830
EBITDA
(50,327)
36,477
(48,773)
EV/EBITDA
61.78
Interest
28,818
71,734
88,727
Interest/NOPBT
465.59%